文献速递甲状腺核医学核素与放射性配体治疗

短期甲状腺激素撤退能否作为分化型甲状腺癌患者放射性碘残余消融的有效策略

Could short thyroid hormone withdrawal be an effective strategy for radioiodine remnant ablation in differentiated thyroid cancer patients?
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-02-19

本研究评估了分化型甲状腺癌患者术后行放射性碘残余消融前,短期(14天)甲状腺激素撤退能否达到足够TSH水平(30 mU/l),并分析撤退时长与疗效的关系。222例患者中85例接受2周撤退(A组),137例接受3-4周撤退(B组),消融时所有患者TSH均≥30 mU/l。中位随访3.4年后,183例(82%)疗效极佳,39例(18%)疗效不完全;撤退时长和TSH水平与预后无关联,仅消融时甲状腺球蛋白与治疗反应显著相关。

要点

  • 2周甲状腺激素撤退可使所有患者消融时TSH达到≥30 mU/l。
  • 短期与长期撤退组疗效不完全比例无差异。
  • 消融时甲状腺球蛋白是治疗反应的显著相关因素。

核心结论

  • 放射性碘残余消融前,短期2周甲状腺激素撤退是刺激TSH水平的有效方法。
  • 短期撤退与长期撤退的分化型甲状腺癌患者之间,疗效不完全的比例无差异。

研究设计与样本

  • 研究纳入甲状腺切除术后开始左甲状腺素治疗、随后停药行放射性碘残余消融的分化型甲状腺癌患者222例。
  • 按甲状腺激素撤退时长分为A组(2周,85例)和B组(3-4周,137例)。
  • 采用临床、生化及影像数据评估疗效,并通过单变量和多变量分析(纳入主要分化型甲状腺癌预后因素)评估撤退时长和TSH水平对预后的影响。

主要发现

  • 放射性碘残余消融时所有患者TSH水平均≥30 mU/l。
  • 中位随访3.4年后,183例(82%)疗效极佳,39例(18%)疗效不完全。
  • Kaplan-Meier疗效曲线显示,消融时甲状腺球蛋白、肿瘤大小和淋巴结状态与预后显著相关。
  • 甲状腺激素撤退时长和TSH水平与预后未发现关联。
  • 多变量Cox模型显示,仅消融时甲状腺球蛋白与治疗反应显著相关。

关键数值与推荐

  • 当前指南推荐分化型甲状腺癌放射性碘残余消融前甲状腺激素撤退3-4周。
  • 本研究中达到足够TSH水平的界值为30 mU/l。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Current guidelines recommend thyroid hormone withdrawal (THW) of 3-4 weeks before radioiodine remnant ablation (RRA) of differentiated thyroid carcinoma (DTC). We aimed to evaluate (1) the reliability of a shorter THW (i.e., 14 days) to achieve adequate TSH levels (i.e., 30 mU/l), (2) the association between length of THW and response to therapy, and (3) the potential association between pre-ablation TSH levels and patients' outcome. METHODS: After thyroidectomy, all patients started LT4 therapy, which was subsequently discontinued in order to perform RRA. Patients were broken down into two groups according to the length of THW: group A, 2 weeks of THW, and group B, 3-4 weeks of THW. We used clinical, biochemical, and imaging data to evaluate patients' outcome. By means of univariate and multivariate analysis, including main DTC prognostic factors, we assessed the impact of THW length and TSH levels on patients' outcome. RESULTS: We evaluated 222 patients, 85 of whom were treated with RRA after a THW period of 2 weeks (group A). All other 137 patients underwent RRA after 3-4 weeks THW (group B). At the time of RRA all patients presented TSH levels ≥30 mU/l. After a median follow-up time of 3.4 years, we found 183 patients (82%) with excellent response to treatment and 39 patients (18%) showing incomplete response. Kaplan-Meier response to therapy curves showed that ablation-Tg, tumor size, and lymph node status were significantly associated with prognosis; no associations were found between THW length, TSH levels, and prognosis. Multivariate Cox model showed that only ablation-Tg was significantly associated with treatment response. CONCLUSIONS: Prior to RRA, a short 2-week THW is an effective method to stimulate TSH levels. No difference in terms of incomplete response to treatment was observed between DTC patients prepared for RRA with a short THW and those with the long THW.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Piccardo A, Puntoni M, Ferrarazzo G, et al. Could short thyroid hormone withdrawal be an effective strategy for radioiodine remnant ablation in differentiated thyroid cancer patients? Eur J Nucl Med Mol Imaging. 2018. PMID: 29460027. doi:10.1007/s00259-018-3955-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。